Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 9/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | BCL6 | P41182 | 2/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345727 | 1.00 | HCRTR1 (0.48) | HCRTR1HCRTR2MAPTPTPN11PDE2A | |
| SCHEMBL29364564 | 0.81 | HCRTR1 (0.53) | HCRTR1HCRTR2MAPTPDE2APDE10A | |
| SCHEMBL6924601 | 0.81 | HCRTR1 (0.53) | HCRTR1HCRTR2MAPTPDE2APDE10A | |
| SCHEMBL6772714 | 0.80 | HTR3A (0.57) | PTPN11PDE10AHTR3A | |
| SCHEMBL6772712 | 0.80 | HTR3A (0.57) | PTPN11PDE10AHTR3A | |
| SCHEMBL30345365 | 0.80 | HTR3A (0.57) | PTPN11PDE10AHTR3A | |
| SCHEMBL23744191 | 0.80 | HTR3A (0.57) | PTPN11PDE10AHTR3A | |
| SCHEMBL30345535 | 0.80 | HTR3A (0.57) | PTPN11PDE10AHTR3A | |
| Hydrochloric Acid SCHEMBL29367009 | 0.80 | HCRTR1 (0.53) | HCRTR1HCRTR2MAPTPDE2APDE10A | |
| SCHEMBL26089984 | 0.79 | HCRTR1 (0.52) | HCRTR1HCRTR2MAPTPDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | HCRTR1 210/4885HCRTR2 183/4885MAPT 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.